MapLight Therapeutics, Inc.
ML-004
autism spectrum disorder
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ML-004 for autism spectrum disorder is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Data support potential development of ML-004 for irritability associated with ASD, an indication with high unmet need and an established regulatory path”